Stably Expressing
EGFR Mutant Cell Lines
Signosis offers a comprehensive panel of stably expressing EGFR mutant cell lines representing key mutation classes for studying cancer biology, drug resistance mechanisms, and screening targeted therapies.
Introduction
Epidermal Growth Factor Receptor (EGFR) mutations play a central role in oncogenic signaling, particularly in non‑small cell lung cancer (NSCLC) adenocarcinoma, where specific alterations drive tumor proliferation and therapeutic response. These alterations activate downstream signaling pathways such as RAS/RAF/MEK/ERK and PI3K/AKT, promoting cell proliferation, survival, and metastatic potential.
Classic EGFR alterations such as Exon 19 deletions (Del19) and L858R show strong initial responses to 1st/2nd generation tyrosine kinase inhibitors (TKIs), but on‑target resistance mutations like T790M, C797S, and Exon 20 insertions frequently emerge. Signosis offers multiple stable cell lines expressing clinically relevant genotypes of mutant EGFR that enable precise EC50 determination, resistance profiling, and high-throughput screening.
Classical-like Mutations
Mutations typically sensitive to first- and second-generation EGFR TKIs:
-
L858R
-
Del19
-
Del19 + T790M
-
A767_dupASV
Note: Del19 + T790M is both a classical driver and resistance mutation.
Exon 20 Loop Insertion Mutations
Insertions in the loop at the C-terminal end of the αC-helix in exon 20, often causing drug resistance:
-
H773_V774insNPH
-
D770_N771insSVD
-
H773_V774insH
-
A763_Y764insFQEA
-
M766_A767insAI
-
Y764_V765insHH
T790M-like Mutations
Mutations that generally confer resistance to first- and second-generation EGFR TKIs:
-
T790M
-
L792H
-
C797S
-
Del19 + T790M
-
Mutations with T790M and/or C797S
P-loop and αC-helix Compression (PACC) Mutations
Mutations affecting the ATP-binding pocket that cause compression, impacting drug binding affinity.
-
L718Q
-
L792H
Principle
Signosis mainly utilizes the Ba/F3, an IL-3-dependent murine pro-B cell line, to provide a definitive readout of inhibitor efficacy. By stably expressing human EGFR mutants, these cells undergo a phenotypic switch, rendering their survival entirely dependent on the oncogenic EGFR signaling pathway rather than IL-3.
This cytokine-independent growth model allows for precise, quantitative measurement of a compound's ability to inhibit specific EGFR variants. When a candidate TKI successfully targets the mutant EGFR protein, it triggers cell death, allowing researchers to determine EC50 with high sensitivity and minimal basal noise.
Comprehensive EGFR Mutant Cell Line Collection
Signosis offers a wide variety of EGFR mutant cell lines that reflect key mutation classes with distinct biological functions and drug sensitivity profiles to supports advanced cancer research and drug development, including:
Signosis EGFR Cell Lines
FAQ
Can these cell lines be used for TKI resistance studies?
Yes. Ba/F3 lines with compound mutations (Del19+T790M, L858R+C797S) enable evaluation of 1st, 2nd, 3rd, and emerging 4th-generation EGFR TKIs, accurately modeling clinically observed resistance patterns.
Are the these cell lines validated?
All cell lines undergo single-cell clonal expansion, genotypic confirmation (sequencing), and phenotypic verification (Western blot) to confirm activity for consistent performance.
Are these products for diagnostic use?
No—for research use only. Not intended for diagnostic, therapeutic, or clinical applications.
How do Ba/F3 EGFR lines differ from parental Ba/F3 cells?
Parental Ba/F3 cells require IL-3 for survival. Mutant EGFR Ba/F3 lines are engineered for IL-3 independence, with growth driven solely by oncogenic EGFR signaling—ideal for direct TKI potency measurement via cell viability.
Are these suitable for high-throughput screening (HTS)?
Yes. Optimized for 96- and 384-well formats with high signal-to-noise ratios, consistent growth rates, and reproducible EC50 values across plates.
What about CHO EGFR cell lines?
CHO lines provide high-yield EGFR protein expression for biochemical assays, ligand binding, structural studies, and validation complementary to Ba/F3 functional screening.
Do you offer custom EGFR mutant cell lines?
Yes. Signosis provides expedited custom stable cell line development (6-8 weeks) for novel mutations, compound genotypes, or specific research needs. Contact us
How are these cell lines validated?
Single-cell clonal expansion, genotypic confirmation (sequencing), phenotypic verification (Western blot),
